Modality
Gene Therapy
MOA
KRASG12Di
Target
GIP-R
Pathway
Sphingolipid
Bladder CaPancreatic CaMS
Development Pipeline
Preclinical
~Mar 2012
→ ~Jun 2013
Phase 1
~Sep 2013
→ ~Dec 2014
Phase 2
~Mar 2015
→ ~Jun 2016
Phase 3
~Sep 2016
→ ~Dec 2017
NDA/BLA
Mar 2018
→ Aug 2030
NDA/BLACurrent
NCT04283936
17 pts·Pancreatic Ca
2021-08→2030-08·Recruiting
NCT03478696
2,606 pts·MS
2018-03→2029-02·Recruiting
2,623 total pts2 indications
Approved
CompletedCurrentUpcoming
Catalysts (2)
2029-02-242.9y awayPh3 Readout· MS
2030-08-084.4y awayPh3 Readout· Pancreatic Ca
Trial Timeline
2018Q2Q3Q42019Q2Q3Q42020Q2Q3Q42021Q2Q3Q42022Q2Q3Q42023Q2Q3Q42024Q2Q3Q42025Q2Q3Q42026Q2Q3Q42027Q2Q3Q42028Q2Q3Q42029Q2Q3Q42030Q2Q3Q4
NDA/BLA
Recruit…
NDA/BLA
Recruit…
Catalysts
Ph3 Readout
2029-02-24 · 2.9y away
MS
Ph3 Readout
2030-08-08 · 4.4y away
Pancreatic Ca
Recruiting|StartCompletionToday
Trials (2)
| NCT | Phase | Indication | Status | N | EP |
|---|---|---|---|---|---|
| NCT04283936 | NDA/BLA | Pancreatic Ca | Recruiting | 17 | eGFR |
| NCT03478696 | NDA/BLA | MS | Recruiting | 2606 | 6MWD |
Competitors (10)
| Drug | Company | Phase | Target | MOA |
|---|---|---|---|---|
| JNJ-5094 | Johnson & Johnson | Phase 2/3 | GIP-R | |
| RHH-3592 | Roche | Phase 1/2 | GIP-R | |
| Doxarasimod | Merck & Co | NDA/BLA | FGFR | |
| Zanusertib | AbbVie | Approved | PCSK9 | |
| Pexarelsin | AstraZeneca | Phase 1 | DLL3 | |
| AZN-5978 | AstraZeneca | Phase 2/3 | GIP-R | |
| Elrarapivir | Regeneron | Phase 1 | GIP-R | |
| Capifutibatinib | Intra-Cellular | Phase 3 | GIP-R | |
| Terarasimod | Krystal Biotech | Phase 1/2 | PI3Kα | |
| DAW-5540 | Day One Bio | Phase 2 | AHR |